OCUL insider plans sale of 6,864 shares

Ocular Therapeutix insider Steve Meyers has filed a Form 144 to sell 6,864 shares of common stock.

Rhea-AI Filing Summary

Ocular Therapeutix insider Steve Meyers has filed a Form 144 to sell 6,864 shares of common stock. The shares are planned to be sold through Morgan Stanley Smith Barney LLC on or about February 12, 2026, with an indicated aggregate market value of $62,034.09.

The 6,864 shares were acquired on February 11, 2026 through restricted stock vesting under a registered plan. Over the past three months, Meyers has already sold 4,408 shares for $37,636.39 and 3,052 shares for $27,903.83. Shares outstanding were 217,691,779 at the time referenced.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the OCUL Form 144 filing by Steve Meyers disclose?

The Form 144 shows Steve Meyers’ intention to sell 6,864 OCUL common shares. These shares were recently acquired through restricted stock vesting, and the planned sale will be executed through Morgan Stanley Smith Barney LLC, subject to Rule 144 conditions and market execution.

How many OCUL shares does Steve Meyers plan to sell under this Form 144?

Steve Meyers plans to sell 6,864 OCUL common shares. The filing lists an aggregate market value of $62,034.09 for this block, based on the market price at the time the notice was prepared for the anticipated sale date.

When were the OCUL shares in the Form 144 acquired and how?

The 6,864 OCUL shares were acquired on February 11, 2026. They came from restricted stock vesting under a registered compensation plan, with the issuer as the source, and no separate cash payment noted for this acquisition in the filing.

What prior OCUL stock sales by Steve Meyers are reported in the last 3 months?

The filing reports two recent OCUL stock sales by Steve Meyers. He sold 4,408 common shares on February 4, 2026 for $37,636.39 and 3,052 common shares on February 2, 2026 for $27,903.83, all within the three months before this notice.

How many OCUL shares were outstanding at the time of the Form 144 reference?

The notice lists 217,691,779 OCUL common shares outstanding. This figure provides context for the relative size of the 6,864-share proposed sale, but it does not change or register the total outstanding shares itself.

Through which broker will the planned OCUL share sale be executed?

The proposed sale of 6,864 OCUL shares is to be executed through Morgan Stanley Smith Barney LLC. The filing specifies its Executive Financial Services group at 1 New York Plaza, 8th Floor, New York, NY 10004 as the broker handling the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 04:18 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002073994
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	OCULAR THERAPEUTIX, INC.
SEC File Number	001-36554
Address of Issuer	15 Crosby Drive Bedford MASSACHUSETTS 01730
Phone	781-357-4000
Name of Person for Whose Account the Securities are To Be Sold	STEVE MEYERS
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	6864	62034.09	217691779	02/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/11/2026	Restricted stock vesting under a registered plan	Issuer			6864	02/11/2026	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
STEVE MEYERS 15 Crosby Drive Bedford MA 01730	Common	02/04/2026	4408	37636.39
STEVE MEYERS 15 Crosby Drive Bedford MA 01730	Common	02/02/2026	3052	27903.83

144: Remarks and Signature

Remarks
Date of Notice	02/12/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Steve Meyers
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)